Katherine E. Lewis

1.5k total citations
20 papers, 493 citations indexed

About

Katherine E. Lewis is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Katherine E. Lewis has authored 20 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 7 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Oncology. Recurrent topics in Katherine E. Lewis's work include Monoclonal and Polyclonal Antibodies Research (7 papers), T-cell and B-cell Immunology (6 papers) and CAR-T cell therapy research (4 papers). Katherine E. Lewis is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), T-cell and B-cell Immunology (6 papers) and CAR-T cell therapy research (4 papers). Katherine E. Lewis collaborates with scholars based in United States, Germany and Sweden. Katherine E. Lewis's co-authors include Stacey R. Dillon, Richard García, Olga A. Sergeeva, Peter Hevezi, Shintaro Katayama, Martin Steinhoff, Holger Schrumpf, M Feld, Gareth Muirhead and Bernhard Homey and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Katherine E. Lewis

17 papers receiving 482 citations

Peers

Countries citing papers authored by Katherine E. Lewis

Since Specialization

Citations

This map shows the geographic impact of Katherine E. Lewis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine E. Lewis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine E. Lewis more than expected).

Fields of papers citing papers by Katherine E. Lewis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine E. Lewis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine E. Lewis. The network helps show where Katherine E. Lewis may publish in the future.

Co-authorship network of co-authors of Katherine E. Lewis

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine E. Lewis. A scholar is included among the top collaborators of Katherine E. Lewis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine E. Lewis. Katherine E. Lewis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P104 Upregulation of both APRIL and BAFF in systemic lupus erythematosus suggests non-redundant roles, further revealed by potent dual inhibition with povetacicept (TACI vTD-Fc; ALPN-303) 2024 ·SHILAP Revista de lepidopterología ·Katherine E. Lewis, (unknown), (unknown), Tiffany C. Blair, Amanda Enstrom, Lawrence S. Evans, Armand Bankhead, İsmail Şimşek, Stanford L. Peng, Stacey R. Dillon	1
2	Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist, Suppresses Disease in a Mouse Model of Autoimmune Encephalitis (S4.005) 2024 ·Neurology ·Katherine E. Lewis, (unknown), (unknown), (unknown), (unknown), Stacey R. Dillon, Stanford L. Peng	1
3	Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101) 2023 ·Arthritis & Rheumatology ·Stacey R. Dillon, Lawrence S. Evans, Katherine E. Lewis, (unknown), Tiffany C. Blair, Sherri Mudri, (unknown), Steven D. Levin, Janhavi Bhandari, (unknown), Martin F. Wolfson, Pamela M. Holland, Mark W. Rixon, Stanford L. Peng	7
4	Systemic Administration of Acazicolcept, a Dual CD28 and Inducible T cell Costimulator Inhibitor, Ameliorates Experimental Autoimmune Uveitis 2023 ·Translational Vision Science & Technology ·Leslie Wilson, Katherine E. Lewis, Lawrence S. Evans, Stacey R. Dillon, Kathryn L. Pepple	2
5	Povetacicept (ALPN-303), a Potent Dual BAFF/APRIL Antagonist in Development for the Treatment of Autoimmune Cytopenias, Suppresses Disease in a Mouse Model of Autoimmune Hemolytic Anemia 2023 ·Blood ·Katherine E. Lewis, (unknown), (unknown), Amanda Enstrom, Armand Bankhead, Stanford L. Peng, Stacey R. Dillon	3
6	The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity 2022 ·Nature Communications ·Mark Maurer, Katherine E. Lewis, Joseph L. Kuijper, (unknown), Chelsea J. Gudgeon, Siddarth Chandrasekaran, Sherri Mudri, (unknown), (unknown), Martin F. Wolfson, Mark W. Rixon, Ryan Swanson, Stacey R. Dillon, Steven D. Levin, (unknown), Masato Akutsu, Derek T. Logan, Björn Walse, Kristine M. Swiderek, Stanford L. Peng	20
7	OP0039 ALPN-303, AN ENHANCED, POTENT DUAL BAFF/APRIL ANTAGONIST ENGINEERED BY DIRECTED EVOLUTION FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER B CELL-RELATED AUTOIMMUNE DISEASES 2021 ·Annals of the Rheumatic Diseases ·Stacey R. Dillon, Lawrence S. Evans, Katherine E. Lewis, (unknown), Mark W. Rixon, Joseph L. Kuijper, Daniel Demonte, Janhavi Bhandari, Steven D. Levin, (unknown), Sherri Mudri, Susan Bort, (unknown), (unknown), (unknown), Chelsea J. Gudgeon, (unknown), Martin F. Wolfson, Jan Hillson, Stanford L. Peng	3
8	Intravitreal Injection of ALPN-101, a Dual ICOS/CD28 Antagonist, Suppresses Ocular Inflammation in Rat Experimental Autoimmune Uveitis 2020 ·Investigative Ophthalmology & Visual Science ·Kathryn L. Pepple, Leslie Wilson, Katherine E. Lewis, Lawrence S. Evans, Stacey R. Dillon	1
9	Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains 2020 ·Frontiers in Immunology ·Steven D. Levin, Lawrence S. Evans, Susan Bort, Erika Rickel, Katherine E. Lewis, (unknown), Joe Hoover, (unknown), David La, Martin F. Wolfson, Mark W. Rixon, Stacey R. Dillon, M. G. Kornacker, Ryan Swanson, Stanford L. Peng	9
10	P156 ALPN-101, A FIRST-IN-CLASS DUAL ICOS/CD28 ANTAGONIST, DEMONSTRATES EFFICACY IN PATIENT-DERIVED PBMC IN VITRO AND IN AN IN VIVO T CELL TRANSFER MODEL OF CHRONIC INFLAMMATORY BOWEL DISEASE (IBD) 2020 ·Gastroenterology ·Kristine M. Swiderek, Stacey R. Dillon, John L. Moore, Susan Bort, Sherri Mudri, Katherine E. Lewis, Mark W. Rixon, Janhavi Bhandari, Stanford L. Peng	1
11	Alpn-101, a Dual ICOS/CD28 Antagonist, Demonstrates Potent and Dose-Dependent Suppression of Graft Vs. Host Disease (GvHD) in a Human/NSG Mouse Xenograft Model, with Activity Superior to CD28 or ICOS Single Pathway Antagonists 2019 ·Biology of Blood and Marrow Transplantation ·Stacey R. Dillon, (unknown), Katherine E. Lewis, Lawrence S. Evans, Sherri Mudri, Rebecca Wu, Kristine M. Swiderek, Stanford L. Peng	2
12	A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgD) Potently Suppresses Human Mixed Lymphocyte Reactions and Human/NSG Mouse Xenograft Graft vs. Host Disease (GvHD) 2018 ·Biology of Blood and Marrow Transplantation ·Stacey R. Dillon, Katherine E. Lewis, Ryan Swanson, Lawrence S. Evans, M. G. Kornacker, Steven D. Levin, Martin F. Wolfson, Erika Rickel, Susan Bort, Aaron M. Moss, (unknown), Janhavi Bhandari, (unknown), Joe Hoover, Mark W. Rixon, Stanford L. Peng	2
13	Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models 2017 ·OncoImmunology ·Katherine E. Lewis, Mark Selby, Gregg Masters, Juan W. Valle, (unknown), (unknown), Richard García, (unknown), Kimberly S. Waggie, Matthew S. Holdren, Joseph F. Grosso, Alan J. Korman, Maria Jure–Kunkel, Stacey R. Dillon	51
14	The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves 2016 ·Journal of Allergy and Clinical Immunology ·M Feld, Richard García, Joerg Buddenkotte, Shintaro Katayama, Katherine E. Lewis, Gareth Muirhead, Peter Hevezi, (unknown), Holger Schrumpf, Kaarel Krjutškov, Olga A. Sergeeva, Hans Werner Müller, Sophia Tsoka, Juha Kere, Stacey R. Dillon, Martin Steinhoff, Bernhard Homey	213
15	Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL‐31 neutralizing antibody 2016 ·Journal of the European Academy of Dermatology and Venereology ·Katherine E. Lewis, Matthew S. Holdren, Mark Maurer, (unknown), Brent Meengs, (unknown), Kelly Byrnes-Blake, Jeremy A. Freeman, (unknown), Anitra C. Wolf, Nels Hamacher, Mark W. Rixon, Stacey R. Dillon	34
16	Quantification of Human Mabs in Mouse Tissues Using Generic Affinity Enrichment Procedures and LC–MS Detection 2014 ·Bioanalysis ·Bogdan Sleczka, John T. Mehl, David J. Shuster, Katherine E. Lewis, (unknown), Ragini Vuppugalla, Surendran Rajendran, Celia D’Arienzo, Timothy Olah	20
17	Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models. 2013 ·Journal of Clinical Oncology ·Maria Jure–Kunkel, Mark Selby, Katherine E. Lewis, Gregg Masters, Juan W. Valle, Joseph F. Grosso, (unknown), (unknown), Richard García, Matthew S. Holdren, Alan J. Korman, Stacey R. Dillon	7
18	Recombinant Soluble Human FcγR1A (CD64A) Reduces Inflammation in Murine Collagen-Induced Arthritis 2009 ·The Journal of Immunology ·Jeff L. Ellsworth, Nels Hamacher, Brandon Harder, (unknown), Thomas R. Bukowski, Kelly Byrnes-Blake, (unknown), Colleen Oliver, Kimberly S. Waggie, (unknown), (unknown), Mark W. Rixon, Katherine E. Lewis	25
19	Targeting Immune Complex-Mediated Hypersensitivity with Recombinant Soluble Human FcγRIA (CD64A) 2008 ·The Journal of Immunology ·Jeff L. Ellsworth, Mark Maurer, Brandon Harder, Nels Hamacher, (unknown), Kenneth B. Lewis, (unknown), Kelly Byrnes-Blake, (unknown), Kimberly S. Waggie, Jennifer Visich, Katherine E. Lewis	25
20	A Glycoprotein Hormone Expressed in Corticotrophs Exhibits Unique Binding Properties on Thyroid-Stimulating Hormone Receptor 2005 ·Molecular Endocrinology ·Shannon Okada, Jeff L. Ellsworth, Diane M. Durnam, Harald S. Haugen, James L. Holloway, Merideth L. Kelley, Katherine E. Lewis, (unknown), Paul O. Sheppard, (unknown), Kimberly S. Waggie, Anitra C. Wolf, Lena Yao, Philippa J. Webster	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact